IA Trial Radar
O estudo clínico NCT07170657 (Teen RISE) para Ideação suicida, Tentativa de suicídio, Ansiedade, Depression Disorders está em recrutamento. Consulte a visualização em cartões do Radar de Estudos Clínicos e as ferramentas de descoberta de IA para ver todos os detalhes. Ou pergunte qualquer coisa aqui.
Um estudo corresponde aos critérios do filtro
Visualização em cartões

Teen Recovery Through Inspiration, Support, and Empowerment (Teen RISE) 40 Inovador

Em recrutamento
Os detalhes do estudo clínico estão disponíveis principalmente em inglês. No entanto, a IA Trial Radar pode ajudar! Basta clicar em 'Explicar o estudo' para visualizar e discutir as informações do estudo no idioma selecionado.
O estudo clínico NCT07170657 (Teen RISE) é um estudo intervencionista para Ideação suicida, Tentativa de suicídio, Ansiedade, Depression Disorders. Seu status atual é: em recrutamento. O estudo começou em 5 de novembro de 2025 e pretende incluir 40 participantes. Coordenado por o Centro Médico Sudoeste da Universidade do Texas e deve ser concluído em 1 de novembro de 2026. Essas informações foram atualizadas no ClinicalTrials.gov em 30 de janeiro de 2026.
Resumo
The goal of this pilot study is to test the effectiveness of a novel intervention for teenagers (ages 15-18) with mental health conditions who have been released from an acute care psychiatric facility. The intervention aims to reduce suicidality, depression, anxiety, re-hospitalization, and to improve mental health recovery by using an online recovery education and support program.

The current standard of care (SOC...

Mostrar mais
Descrição detalhada

Purpose:

  • This is a pilot study to test the effectiveness of a novel intervention aimed at reducing the incidences of suicidality, depression, anxiety, re-hospitalization rates, and improving mental health recovery by utilizing outpatient services, and medication adherence for high school teenagers ages 15-18, with mental health conditions verses the standard of care (SOC) at discharge which only provides a dischar...
Mostrar mais
Título oficial

Teen Recovery Through Inspiration, Support, and Empowerment (RISE)

Condições médicas
Ideação suicidaTentativa de suicídioAnsiedadeDepression Disorders
Publicações
Artigos científicos e trabalhos de pesquisa publicados sobre este estudo clínico:
Mostrar mais
Outros IDs do estudo
  • Teen RISE
  • STU-2024-0493
Número NCT
Data de início (real)
2025-11-05
Última atualização postada
2026-01-30
Data de conclusão (estimada)
2026-11
Inscrição (estimada)
40
Tipo de estudo
Intervencionista
FASE
N/A
Status
Em recrutamento
Palavras-chave
Peer Support Specialist (PSS)
Recovery Education and Support (RES) Program
Teenage
High School Teen
UT Southwestern Medical Center
Mental Health Recovery
Online
Virtual
Propósito principal
Tratamento
Alocação do design
Randomizado
Modelo de intervenção
Paralelo
Cegamento (Mascaramento)
Nenhum (Aberto)
Braços / Intervenções
Grupo de participantes/BraçoIntervenção/Tratamento
ExperimentalCohort A: Intervention Group with PSS, TP, and RES
Virtual one on one meetings peer support specialist (PSS), trained peer (TP) using recovery education and support program (RES). Group meetings with PSS, TP, and other participants. Qualitative and quantitative assessments.
Peer Support Services Recovery
A program of mental health recovery through one-on-one and small group meetings with a PSS and TP using RES for individuals recently discharged from an acute care psychiatric facility.
Nenhuma intervençãoCohort B: Standard of Care
Scheduled telephone call visit with a member of the research team. Qualitative and quantitative assessments.
N/A
Desfecho primário
Medida de desfechoDescrição da medidaPrazo
Change in Suicidal Ideation as measured by C-SSRS at 2 weeks from baseline
Change in suicidal ideation is measured by Columbia Suicide Severity Rating Scale (C-SSRS) at 2 weeks from baseline using both the baseline and since last visit assessment versions. Scoring of the assessment indicates severity. The C-SSRS consists of 16 questions that ask about suicidal ideation and behaviors (the first 10 questions comprise the ideation subscale and the last 6 comprise the behavior subscale). Total score ranges for suicidal ideation from a minimum of 0 (corresponding to no suicidal ideation) to a maximum of 5 (representing active suicidal ideation with plan and intent). Total score ranges for suicidal behavior from a minimum of 0 (corresponding to no suicidal behavior) to a maximum of 5 (representing active suicidal behavior).
Baseline, 2 weeks
Change in Suicidal Ideation as measured by C-SSRS at 4 weeks from baseline
Change in suicidal ideation is measured by Columbia Suicide Severity Rating Scale (C-SSRS) at 4 weeks from baseline using both the baseline and since last visit assessment versions. Scoring of the assessment indicates severity. The C-SSRS consists of 16 questions that ask about suicidal ideation and behaviors (the first 10 questions comprise the ideation subscale and the last 6 comprise the behavior subscale). Total score ranges for suicidal ideation from a minimum of 0 (corresponding to no suicidal ideation) to a maximum of 5 (representing active suicidal ideation with plan and intent). Total score ranges for suicidal behavior from a minimum of 0 (corresponding to no suicidal behavior) to a maximum of 5 (representing active suicidal behavior).
Baseline, 4 weeks
Change in Suicidal Ideation as measured by C-SSRS at 6 weeks from baseline
Change in suicidal ideation is measured by Columbia Suicide Severity Rating Scale (C-SSRS) at 6 weeks from baseline using both the baseline and since last visit assessment versions. Scoring of the assessment indicates severity. The C-SSRS consists of 16 questions that ask about suicidal ideation and behaviors (the first 10 questions comprise the ideation subscale and the last 6 comprise the behavior subscale). Total score ranges for suicidal ideation from a minimum of 0 (corresponding to no suicidal ideation) to a maximum of 5 (representing active suicidal ideation with plan and intent). Total score ranges for suicidal behavior from a minimum of 0 (corresponding to no suicidal behavior) to a maximum of 5 (representing active suicidal behavior).
Baseline, 6 weeks
Change in Suicidal Ideation as measured by C-SSRS at 8 weeks from baseline
Change in suicidal ideation is measured by Columbia Suicide Severity Rating Scale (C-SSRS) at 8 weeks from baseline using both the baseline and since last visit assessment versions. Scoring of the assessment indicates severity. The C-SSRS consists of 16 questions that ask about suicidal ideation and behaviors (the first 10 questions comprise the ideation subscale and the last 6 comprise the behavior subscale). Total score ranges for suicidal ideation from a minimum of 0 (corresponding to no suicidal ideation) to a maximum of 5 (representing active suicidal ideation with plan and intent). Total score ranges for suicidal behavior from a minimum of 0 (corresponding to no suicidal behavior) to a maximum of 5 (representing active suicidal behavior).
Baseline, 8 weeks
Desfecho secundário
Medida de desfechoDescrição da medidaPrazo
Changes in symptoms associated with anxiety as measured by GAD 7 at 2 weeks
A reduction of anxiety symptoms and rates of occurrence will be measured using the Generalized Anxiety Disorder (GAD) 7 - a widely used screening tool for assessing the severity of generalized anxiety disorder (GAD) and consists of 7 items that evaluate anxiety symptoms with 4 response options: 0- "Not at all", 1-"Several days", 2-"More than half the days", 3-"Nearly every day". Total score can range from 0 to 21 with higher scores indicating higher levels of anxiety.
Baseline, 2 weeks
Changes in symptoms associated with anxiety as measured by GAD 7 at 4 weeks
A reduction of anxiety symptoms and rates of occurrence will be measured using the Generalized Anxiety Disorder (GAD) 7 - a widely used screening tool for assessing the severity of generalized anxiety disorder (GAD) and consists of 7 items that evaluate anxiety symptoms with 4 response options: 0- "Not at all", 1-"Several days", 2-"More than half the days", 3-"Nearly every day". Total score can range from 0 to 21 with higher scores indicating higher levels of anxiety.
Baseline, 4 weeks
Changes in symptoms associated with anxiety as measured by GAD 7 at 6 weeks
A reduction of anxiety symptoms and rates of occurrence will be measured using the Generalized Anxiety Disorder (GAD) 7 - a widely used screening tool for assessing the severity of generalized anxiety disorder (GAD) and consists of 7 items that evaluate anxiety symptoms with 4 response options: 0- "Not at all", 1-"Several days", 2-"More than half the days", 3-"Nearly every day". Total score can range from 0 to 21 with higher scores indicating higher levels of anxiety.
Baseline, 6 weeks
Changes in symptoms associated with anxiety as measured by GAD 7 at 8 weeks
A reduction of anxiety symptoms and rates of occurrence will be measured using the Generalized Anxiety Disorder (GAD) 7 - a widely used screening tool for assessing the severity of generalized anxiety disorder (GAD) and consists of 7 items that evaluate anxiety symptoms with 4 response options: 0- "Not at all", 1-"Several days", 2-"More than half the days", 3-"Nearly every day". Total score can range from 0 to 21 with higher scores indicating higher levels of anxiety.
Baseline, 8 weeks
Changes in symptoms associated with depression as measured by PHQ-9 at 2 weeks
A reduction of depression symptoms and rates of occurrence will be measured using the Patient Health Questionnaire (PHQ) - a self reported inventory used as a screening and diagnostic tool for depression. The PHQ-9 is a 9-item self-reported instrument that measures depression symptoms. Respondents are asked how much each symptom has bothered them over the past 2 weeks, with response options of "not at all", "several days", "more than half the days", and "nearly every day", scored as 0, 1, 2, and 3. The scale can range from 0 to 27, with higher scores indicating higher levels of depression.
Baseline, 2 weeks
Changes in symptoms associated with depression as measured by PHQ-9 at 4 weeks
A reduction of depression symptoms and rates of occurrence will be measured using the Patient Health Questionnaire (PHQ) - a self reported inventory used as a screening and diagnostic tool for depression. The PHQ-9 is a 9-item self-reported instrument that measures depression symptoms. Respondents are asked how much each symptom has bothered them over the past 2 weeks, with response options of "not at all", "several days", "more than half the days", and "nearly every day", scored as 0, 1, 2, and 3. The scale can range from 0 to 27, with higher scores indicating higher levels of depression.
Baseline, 4 weeks
Changes in symptoms associated with depression as measured by PHQ-9 at 6 weeks
A reduction of depression symptoms and rates of occurrence will be measured using the Patient Health Questionnaire (PHQ) - a self reported inventory used as a screening and diagnostic tool for depression. The PHQ-9 is a 9-item self-reported instrument that measures depression symptoms. Respondents are asked how much each symptom has bothered them over the past 2 weeks, with response options of "not at all", "several days", "more than half the days", and "nearly every day", scored as 0, 1, 2, and 3. The scale can range from 0 to 27, with higher scores indicating higher levels of depression.
Baseline, 6 weeks
Changes in symptoms associated with depression as measured by PHQ-9 at 8 weeks
A reduction of depression symptoms and rates of occurrence will be measured using the Patient Health Questionnaire (PHQ) - a self reported inventory used as a screening and diagnostic tool for depression. The PHQ-9 is a 9-item self-reported instrument that measures depression symptoms. Respondents are asked how much each symptom has bothered them over the past 2 weeks, with response options of "not at all", "several days", "more than half the days", and "nearly every day", scored as 0, 1, 2, and 3. The scale can range from 0 to 27, with higher scores indicating higher levels of depression.
Baseline, 8 weeks
Assistente de participação
Critérios de elegibilidade

Idades elegíveis
Criança, Adulto
Idade mínima
15 Years
Sexos elegíveis
Todos
  • Chief complaint of suicidal ideation, suicide attempt, depression, and/or anxiety
  • recently discharged from inpatient care or from emergency department
  • men and women ages 15-18 years old

- primary diagnosis of: substance use disorder, schizophrenia spectrum, intellectual development disorder, autism spectrum disorder (level II or III)
University of Texas Southwestern Medical Center logoCentro Médico Sudoeste da Universidade do Texas
Responsável pelo estudo
Joseph Guillory, Investigador principal, Principal Investigator, University of Texas Southwestern Medical Center
Contato central do estudo
Contato: Cameron M Pham, 214-648-4885, [email protected]
1 Locais do estudo em 1 países

Texas

The University of Texas Southwestern Medical Center, Dallas, Texas, 75390, United States
Em recrutamento